Investigational drug · Phase 3
TQB2825
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Diffuse Large Cell B-lymphoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5
Any phase or sponsor naming "TQB2825"
First trial start
2025
Mar 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQB2825", any sponsor or status.
Conditions studied
As listed on its trial records.
- Follicular Lymphoma
- Diffuse Large B Cell Lymphoma
- Diffuse Large Cell B-lymphoma
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "TQB2825" as an intervention, largest first.
- Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular LymphomaPivotal-lookingNot yet recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry
NCT07187960 · 228 participants (planned) · Start Nov 2025 · Primary completion Oct 2028
Drug: TQB2825 Injection; Rituximab Injection · For: Follicular Lymphoma
Sites: Beijing, China; Chongqing, China; Lanzhou, China · 28 sites in all
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT05489276 · 180 participants (planned) · Start Mar 22, 2022 · Primary completion Oct 2023
Drug: TQB2825 injection · For: Hematological Tumors
Sites: Beijing, China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06829771 · 90 participants (planned) · Start Apr 23, 2025 · Primary completion May 2026
Drug: TQB2825 injection +R-CHOP regimen; TQB2825 injection + GemOx · For: Diffuse Large B Cell Lymphoma
Sites: Bengbu, China; Ma’anshan, China; Beijing, China · 25 sites in all
- Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological MalignanciesNot yet recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry
NCT07110194 · 75 participants (planned) · Start Sep 2025 · Primary completion Mar 2026
Drug: TQB2825 Injection (Subcutaneous Injection) · For: CD20-positive Hematological Malignancies
Sites: Beijing, China
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry
NCT06854445 · 55 participants (planned) · Start Mar 12, 2025 · Primary completion Oct 2025
Drug: TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection · For: Diffuse Large Cell B-lymphoma
Sites: Wuhu, China; Xiamen, China; Lanzhou, China · 24 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Follicular Lymphoma
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- CC-99282BMS-986369, GolcadomidePhase 37 trials
Bristol Myers Squibb · Lymphoma, Follicular, Large B-cell Lymphoma, Non-Hodgkin Lymphoma
- MK-1045CN-201Phase 36 trials
Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular
- NemtabrutinibMK-1026, ARQ 531Phase 36 trials
Merck & Co. · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
- TacabrutidegBGB-16673Phase 36 trials
BeOne Medicines (BeiGene) · Chronic Lymphocytic Leukemia, B-cell Malignancy, Small Lymphocytic Lymphoma
- AbexinostatPCI-24781Phase 35 trials
Xynomic Pharmaceuticals, Inc. · Lymphoma, Follicular, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma
- Zugocabtagene geleucelCTX112Phase 23 trials
CRISPR Therapeutics AG · B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy
- and oxaliplatinPhase 22 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.